NasdaqGM:ATRCMedical Equipment
A Look At AtriCure (ATRC) Valuation After Q4 Growth And Recent Analyst Downgrades
Why AtriCure (ATRC) Is Back on Investors’ Radar
AtriCure (ATRC) drew fresh attention after reporting Q4 2025 earnings with 15% revenue growth, followed by share price pressure linked to a JPMorgan downgrade and a reduced price target from UBS.
See our latest analysis for AtriCure.
Despite the recent Q4 earnings momentum, AtriCure’s share price has been under pressure, with a 90 day share price return showing a 28.26% decline and a 1 year total shareholder return showing a 7.15% decline,...